- Home
- MLYS vs VINP Comparison
MLYS vs VINP Comparison
Compare MLYS & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- VINP
- Stock Information
- Founded
- MLYS 2019
- VINP 2009
- Country
- MLYS United States
- VINP Brazil
- Employees
- MLYS N/A
- VINP N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- VINP Investment Managers
- Sector
- MLYS Health Care
- VINP Finance
- Exchange
- MLYS Nasdaq
- VINP Nasdaq
- Market Cap
- MLYS 3.1B
- VINP 714.7M
- IPO Year
- MLYS 2023
- VINP 2021
- Fundamental
- Price
- MLYS $40.67
- VINP $11.51
- Analyst Decision
- MLYS Strong Buy
- VINP Strong Buy
- Analyst Count
- MLYS 6
- VINP 3
- Target Price
- MLYS $42.60
- VINP $13.33
- AVG Volume (30 Days)
- MLYS 1.1M
- VINP 54.7K
- Earning Date
- MLYS 11-12-2025
- VINP 11-13-2025
- Dividend Yield
- MLYS N/A
- VINP 5.75%
- EPS Growth
- MLYS N/A
- VINP N/A
- EPS
- MLYS N/A
- VINP 0.50
- Revenue
- MLYS N/A
- VINP $153,475,995.00
- Revenue This Year
- MLYS N/A
- VINP $68.12
- Revenue Next Year
- MLYS N/A
- VINP $14.85
- P/E Ratio
- MLYS N/A
- VINP $22.89
- Revenue Growth
- MLYS N/A
- VINP 76.11
- 52 Week Low
- MLYS $8.24
- VINP $8.66
- 52 Week High
- MLYS $44.80
- VINP $11.53
- Technical
- Relative Strength Index (RSI)
- MLYS 54.80
- VINP 69.22
- Support Level
- MLYS $39.33
- VINP $10.73
- Resistance Level
- MLYS $41.60
- VINP $11.38
- Average True Range (ATR)
- MLYS 2.06
- VINP 0.26
- MACD
- MLYS -0.92
- VINP 0.02
- Stochastic Oscillator
- MLYS 35.33
- VINP 100.00
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.